Mumbai, Aug. 18 -- The rating on the short-term facilities has been reaffirmed at 'IND A1'.

India Ratings and Research said that the upgrade reflects the strengthening of OSPL's business profile, following the successful commercialisation of its drug device combination (DOC) platform and increasing contribution from commercial glucagon-like peptide-1 (GLP-1) supplies.

India Ratings believes the company has transitioned from a predominantly development-led revenue model to an increasingly commercial supply-led model, supported by multiple customer launches, long-term supply agreements, and capacity expansion.

The demonstrated conversion of development projects into commercial supplies and the ramp-up of commercial revenue have improved ...